ASTRAZENECA

AstraZeneca gets breakthrough status for blood cancer drug

AstraZeneca gets breakthrough status for blood cancer drug

Published 01/08/2017

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014.

AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

[more…]

New test may turn AZ`s Lynparza into precision drug for prostate cancer

New test may turn AZ`s Lynparza into precision drug for prostate cancer

Published 18/06/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

[more…]

Newer type 2 diabetes drugs show heart protective quality in study

Newer type 2 diabetes drugs show heart protective quality in study

Published 19/03/2017

A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a so-called real world study sponsored by AstraZeneca.

[more…]

AstraZeneca receives fresh blow to potassium drug

AstraZeneca receives fresh blow to potassium drug

Published 17/03/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo

AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

[more…]

AstraZeneca ovarian cancer drug slows disease markedly in study

AstraZeneca ovarian cancer drug slows disease markedly in study

Published 14/03/2017

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

AstraZeneca's ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals within the novel PARP inhibitor drug class.

[more…]

AstraZeneca resolves Faslodex patent litigation in U.S.

AstraZeneca resolves Faslodex patent litigation in U.S.

Published 13/07/2016

British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex [more…]

AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep

AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep

Published 21/04/2016

CAMBRIDGE, England AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm [more…]

Sanofi poaches AstraZeneca scientist as new research head

Sanofi poaches AstraZeneca scientist as new research head

Published 29/03/2016

LONDON French drugmaker Sanofi has poached one of AstraZeneca's top scientists to be its new research head in another high-profile departure for the British drugmaker.

[more…]

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

Published 17/12/2015

LONDON AstraZeneca (AZN.L) said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to [more…]

FDA panel votes in favor of approving AstraZeneca’s gout drug

FDA panel votes in favor of approving AstraZeneca’s gout drug

Published 23/10/2015

An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc's gout drug.

All [more…]